Theranica, a prescribed digital therapeutics company developing electroceuticals for migraine and other pain conditions, has announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning Nerivio a new HCPCS Level II code K1023 “Distal Transcutaneous Electrical Nerve Stimulator, Stimulates Peripheral Nerves of the Upper Arm.”

The coding decision covers Theranica’s product Nerivio. The code will become effective on October 1, 2021.

Nerivio, a drug-free remote electrical neuromodulation (REN) device for the acute treatment of migraine in patients 12 years and older, delivers electrical waveform to nerve fibres at the upper arm, to trigger the conditioned pain modulation in the central nervous system, activating the body’s endogenous analgesic mechanism. Nerivio was recently included in the 2021 American Headache Society Consensus Statement for treating migraine.

Level II of the HCPCS is a standardised coding system used primarily to identify products, supplies, and services such as medical devices used outside a physician's office.

Alon Ironi, co-founder and CEO of Theranica, said: “The creation of this new HCPCS code covering Nerivio acknowledges the unique aspects of our technology and helps distinguish our device from other modalities such as TENS. It is an important milestone towards gaining favourable coverage for patients with migraine who are prescribed this therapy. We are pleased with this CMS decision. We are dedicated to delivering safe, effective, first-line, non-pharmaceutical treatments to people living with migraine, and this new unique code is a significant step in making this therapy affordable for them.”